WASHINGTON--(BUSINESS WIRE)--The following statement on the re-introduction of the Innovation Act by House Judiciary Committee Chairman Bob Goodlatte (R-VA) may be attributed to BIO President and CEO Jim Greenwood:
“BIO supports targeted reforms to reign in abusive patent enforcement practices, but any efforts to accomplish this must be done in a way that preserves the patent-based incentives necessary to sustain our nation’s global leadership in biotechnology innovation and the creation of high-wage, high-value jobs throughout our country. BIO is concerned that the Innovation Act as re-introduced today fails to meet that test, by undermining the ability of legitimate patent owners to commercialize their inventions and enforce their patent rights against infringers.
Help employers find you! Check out all the jobs and post your resume.
“BIO supports targeted reforms to reign in abusive patent enforcement practices, but any efforts to accomplish this must be done in a way that preserves the patent-based incentives necessary to sustain our nation’s global leadership in biotechnology innovation and the creation of high-wage, high-value jobs throughout our country. BIO is concerned that the Innovation Act as re-introduced today fails to meet that test, by undermining the ability of legitimate patent owners to commercialize their inventions and enforce their patent rights against infringers.
Help employers find you! Check out all the jobs and post your resume.
